期刊
CELLULAR AND MOLECULAR LIFE SCIENCES
卷 79, 期 7, 页码 -出版社
SPRINGER BASEL AG
DOI: 10.1007/s00018-022-04408-w
关键词
Myostatin; Motor neuron diseases; Muscle atrophy; Activin receptors; type II; Monoclonal antibodies
资金
- Universita degli Studi di Milano within the CRUI-CARE Agreement
- Italian Ministry of Health (Ministero della Salute)
- Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico Grant Ricerca Corrente 2020
Myostatin is a negative regulator of skeletal muscle growth secreted by skeletal myocytes. Inhibition of myostatin has shown potential in enhancing muscle growth and reducing muscle atrophy, making it a promising target for the treatment of motor neuron diseases. This review aims to describe the role of myostatin in these diseases, summarize preclinical and clinical studies of myostatin inhibitors, and discuss the promises and pitfalls of using these inhibitors in human settings, to aid the development of future clinical trials.
Myostatin is a negative regulator of skeletal muscle growth secreted by skeletal myocytes. In the past years, myostatin inhibition sparked interest among the scientific community for its potential to enhance muscle growth and to reduce, or even prevent, muscle atrophy. These characteristics make it a promising target for the treatment of muscle atrophy in motor neuron diseases, namely, amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA), which are rare neurological diseases, whereby the degeneration of motor neurons leads to progressive muscle loss and paralysis. These diseases carry a huge burden of morbidity and mortality but, despite this unfavorable scenario, several therapeutic advancements have been made in the past years. Indeed, a number of different curative therapies for SMA have been approved, leading to a revolution in the life expectancy and outcomes of SMA patients. Similarly, tofersen, an antisense oligonucleotide, is now undergoing clinical trial phase for use in ALS patients carrying the SOD1 mutation. However, these therapies are not able to completely halt or reverse progression of muscle damage. Recently, a trial evaluating apitegromab, a myostatin inhibitor, in SMA patients was started, following positive results from preclinical studies. In this context, myostatin inhibition could represent a useful strategy to tackle motor symptoms in these patients. The aim of this review is to describe the myostatin pathway and its role in motor neuron diseases, and to summarize and critically discuss preclinical and clinical studies of myostatin inhibitors in SMA and ALS. Then, we will highlight promises and pitfalls related to the use of myostatin inhibitors in the human setting, to aid the scientific community in the development of future clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据